Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 1050 of 3499 entries
View as:

Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00305877 Org: User:
Start: 02/28/06 End: 02/29/12 Due: 02/28/13

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00020254 Org: User:
Start: 06/30/00 End: - Due: -

High-Risk Breast Duct Epithelium

Phase: N/A Priority: Normal
NCT ID: NCT00028340 Org: User:
Start: 02/20/03 End: 12/16/22 Due: 12/16/23

Continuing Care and Treatment for Patients With Cancer/AIDS/Skin Disease

Phase: N/A Priority: Normal
NCT ID: NCT00001295 Org: User:
Start: 01/29/92 End: 08/23/16 Due: 08/23/17

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Phase: N/A Priority: Normal
NCT ID: NCT05136196 Org: User:
Start: 12/06/22 End: 01/01/27 Due: 01/01/28

AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT00305656 Org: User:
Start: 01/31/06 End: - Due: -

A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00090545 Org: User:
Start: 09/01/04 End: 04/01/09 Due: 04/01/10

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06317662 Org: User:
Start: 06/05/25 End: 12/31/28 Due: 12/31/29

Apheresis of Patients With Immunodeficiency

Phase: N/A Priority: Normal
NCT ID: NCT01212055 Org: User:
Start: 11/08/10 End: - Due: -

18F-Fluciclovine PET/CT in Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06103838 Org: User:
Start: 03/25/24 End: 12/06/31 Due: 12/06/32

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Phase: N/A Priority: Normal
NCT ID: NCT05564403 Org: User:
Start: 02/09/24 End: 01/21/26 Due: 01/21/27

Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk

Phase: N/A Priority: Normal
NCT ID: NCT00043472 Org: User:
Start: 07/09/03 End: - Due: -

Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00026650 Org: User:
Start: 02/14/00 End: - Due: -

Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies

Phase: N/A Priority: Normal
NCT ID: NCT04847063 Org: User:
Start: 10/19/21 End: 12/30/31 Due: 12/30/32

Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

Phase: N/A Priority: Normal
NCT ID: NCT03366155 Org: User:
Start: 06/24/19 End: 01/31/27 Due: 01/31/28

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01829568 Org: User:
Start: 06/26/13 End: 06/06/26 Due: 06/06/27

Development of a Biologic Specimen Bank for the Study of Early Markers of Lung Cancer Among Tin Miners in Yunnan, China

Phase: N/A Priority: Normal
NCT ID: NCT00340405 Org: User:
Start: 04/30/92 End: 12/31/40 Due: 12/31/41

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04164082 Org: User:
Start: 03/18/20 End: 03/31/26 Due: 03/31/27

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

Phase: N/A Priority: Normal
NCT ID: NCT06364423 Org: User:
Start: 09/03/24 End: 07/01/30 Due: 07/01/31

A Prospective Study of Diet and Cancer in Members of the American Association of Retired Persons

Phase: N/A Priority: Normal
NCT ID: NCT00340015 Org: User:
Start: 10/24/95 End: 02/25/15 Due: 02/25/16

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT01445535 Org: User:
Start: 01/13/09 End: 10/22/20 Due: 10/22/21

Sunitinib to Treat Recurrent Brain Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00923117 Org: User:
Start: 06/30/08 End: 06/30/12 Due: 06/30/13

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02883062 Org: User:
Start: 08/02/17 End: 12/20/20 Due: 12/20/21

Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00002909 Org: User:
Start: 02/28/97 End: - Due: -

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01239355 Org: User:
Start: 12/31/10 End: 02/28/13 Due: 02/28/14